News Wire
Recently published data on Favipiravir as treatment for mild to moderate COVID-19 demonstrates significant improvement in time to clinical cure
– These findings were observed in a Phase 3 clinical trial conducted by Glenmark Pharmaceuticals and has been published by the globally reputed, peer reviewed International Journal of Infectious Diseases
MUMBAI, India, Nov. 23, 2020 /PRNewswire/ — The oral antiviral medication Favipiravir, that prevents the replication phase of the virus life-cycle, leads to significant improvement in clinical cure in patients with mild to moderate COVID-19. These findings were observed in a randomized, controlled Phase 3 clinical study conducted by Glenmark Pharmaceuticals, and the results are now published online in The International Journal of Infectious Diseases (IJID). The IJID is a globally reputed, peer-reviewed, pubmed indexed, open access journal published monthly by the International Society for Infectious Diseases, USA. The published findings will also appear in the print edition of the journal in the coming weeks.
The publication on the study titled “Efficacy and Safety of Favipiravir, an Oral RNA-Dependent RNA Polymerase Inhibitor, in Mild-to-Moderate COVID-19: A Randomized, Comparative, Open-Label, Multicenter, Phase 3 Clinical Trial” was authored by Dr. Zarir .F. Udwadia and other co-authors .
The link to the article is mentioned below
https://authors.elsevier.com/sd/article/S1201-9712(20)32453-X
https://www.sciencedirect.com/science/article/pii/S120197122032453X
The Phase 3 study with antiviral drug Favipiravir, brand name FabiFlu®, was conducted in 150 patients as part of a randomised, open label, multicenter, Phase 3 study. The study aimed to evaluate the efficacy and safety of Favipiravir plus standard supportive care (Favipiravir treatment arm), versus standard supportive care alone (control arm), in mild to moderate patients, randomized within a 48 hour window of testing RT-PCR positive for COVID-19.
Favipiravir was found to provide multiple treatment benefits, demonstrated by faster time to clinical cure, and significantly delayed the need for supportive oxygen therapy. Additionally, patients of confirmed COVID-19 with moderate symptoms were discharged from hospital earlier than those patients that did not receive Favipiravir, with the median time to clinical cure reduced by 2.5 days compared with the control group.
Dr Zarir F. Udwadia. MD, FRCP, FCCP, Breach Candy Hospital, Mumbai, commented “Every claim for the efficacy of a new drug in COVID-19 must be backed by evidence from a clinical trial. Glenmark has done just that with Favipiravir. Their well-designed trial in 150 patients showed Favipiravir resulted in a significantly improved time to clinical cure and rapid viral clearance. Based on this I would consider the use of this anti-viral drug in symptomatic patients with mild to moderate COVID-19. I eagerly await the results of similar trials presently being conducted in Boston and at Stanford.”
Since it was first pronounced a pandemic by the WHO in March, COVID-19 has continued to impact the lives of millions of people globally. As of date, over 50 mn. cases have been reported, with over 1 mn. deaths attributed to this disease. The virus has reportedly spread to all around the world and territories across the globe. Most disease cases are mild to moderate, with symptoms including fever, cough and breathlessness. In severe cases, COVID-19 can cause pneumonia, severe acute respiratory syndrome, kidney failure and death.
Favipiravir is an antiviral medication that works by inhibiting a viral enzyme called RdRP (RNA dependent RNA polymerase), thereby halting the virus’s replication cycle. This helps control the multiplication of the virus and prevents its spread in the patient. This mechanism of action of Favipiravir is novel compared to most antivirals that primarily prevent entry and exit of the virus from cells. Several published reports are now available of the drug’s effectiveness against COVID-19.
Mr. Robert Crockart, Chief Commercial Officer Glenmark Pharmaceuticals, said, “From the first reported case of COVID-19, our every effort was to bring a viable, safe and effective treatment option to patients in a timely manner. It is encouraging to see our trial results now published in a reputed global medical journal, which we hope will support other countries in their fight against this disease.”
Patients in the Glenmark clinical trial received Favipiravir tablets 3,600 mg (1,800 mg BID) (Day 1) + 1,600 mg (800 mg BID) (Day 2 or later) for up to maximum of 14 days, along with standard supportive care. Randomization was stratified based on disease severity into mild and moderate. Favipiravir was well tolerated with no serious adverse events (SAEs) or deaths in the Favipiravir treated arm.
The pre-specified primary endpoint, time from randomisation to cessation of oral shedding of the SARS-CoV-2 virus, demonstrated a 2 day earlier virological cure in the Favipiravir treatment group, though not statistically significant. However, significant improvement in time to clinical cure and other secondary end-points suggest Favipiravir may be beneficial in the treatment of mild-to-moderate COVID-19.
“The study, which was undertaken by Glenmark Pharmaceuticals, at a time when the number of cases for infections were dramatically increasing around the globe, demonstrates Glenmark’s commitment to ensuring all patients have access to affordable medication, to make a positive impact on their quality of life,” said Dr. Monika Tandon, Sr. Vice President & Head – Clinical Development, Global Specialty/Branded Portfolio at Glenmark.
In June 2020, Glenmark received manufacturing and marketing approval from India’s drug regulator for Favipiravir (FabiFlu®), making it the first oral approved medication in India for the treatment of mild to moderate COVID-19. The manufacturing and marketing approval was granted as part of an accelerated approval process, considering the emergency situation of the COVID-19 outbreak in India. The approval’s restricted use entails responsible medication use where every patient must have signed informed consent before treatment initiation.
About The International Journal of Infectious Diseases
The International Journal of Infectious Diseases (IJID) is a peer-reviewed, pubmed indexed, open access journal that publishes original clinical and laboratory-based research, together with reports of clinical trials, reviews, and some case reports dealing with the epidemiology, clinical diagnosis, treatment, and control of infectious diseases with particular emphasis placed on those diseases that are most common in under-resourced countries. IJID is published monthly by the International Society for Infectious Diseases, USA
About Favipiravir
Favipiravir is an RNA-dependent RNA polymerase (RdRp) inhibitor approved for the treatment of novel influenza viruses in Japan and China, with approvals for use in the pandemic across several countries in Asia, Latin America, and the Middle East. Reports of in-vitro studies have demonstrated that Favipiravir can have an effective concentration against the SARS-CoV-2 infection within safe therapeutic dose. Additionally, Favipiravir being an oral formulation – and considering that ∼80% of COVID-19 cases are categorized as mild to moderate – is likely to address unmet clinical needs of a sizeable majority of patient population, which can mostly be treated on an outpatient basis.
About Glenmark Pharmaceuticals Ltd.
Glenmark Pharmaceuticals Ltd. (GPL) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries. Glenmark’s key therapy focus areas globally are respiratory, dermatology and oncology. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenue (SCRIP 100 Rankings published in the year 2019). For more information, visit www.glenmarkpharma.com.
Disclaimer
The foregoing release contains forward-looking statements that can be identified by terminology such as “promising,” “provides treatment benefit,” may reduce,” “suggest,” or similar expressions, or by express or implied discussions regarding potential new indications or labelling for Favipiravir, regarding potential future revenues from Favipiravir, or regarding the long- term impact of a patient’s use of Favipiravir. You should not place undue reliance on these statements. Such forward-looking statements reflect the current views of the Company regarding future events, and involve known and unknown risks, uncertainties and other factors that may cause actual results with Favipiravir to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no guarantee that Favipiravir will be approved for any additional indications or labelling in any market. Nor can there be any guarantee that Favipiravir will achieve any particular levels of revenue in the future. Neither can there be any guarantee regarding the long-term impact of a patient’s use of Favipiravir. In particular, management’s expectations regarding Favipiravir could be affected by, among other things, unexpected clinical trial results, including unexpected NEW clinical data and unexpected additional analysis of existing clinical trial data; unexpected regulatory actions or delays or government regulation generally; the company’s ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry and general public pricing pressures; the impact that the foregoing factors could have on the values attributed to the Glenmark Group’s assets and liabilities as recorded in the Group’s consolidated balance sheet, and other risks and factors referred to in Glenmark Pharmaceutical current Form 20-F on file with the US Securities and Exchange Commission. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those anticipated, believed, estimated or expected. Glenmark Pharmaceuticals is providing the information in this press release as of this date and does not undertake any obligation to update any forward-looking statements contained in this press release as a result of new information, future events or otherwise.
News Wire
Firstsource Partners with Typeface to Launch Agentic Marketing Services
New full-stack offering turns content operations into an agentic growth engine
NEW YORK and MUMBAI, India, April 30, 2026 /PRNewswire/ — Firstsource Solutions Limited (NSE: FSL) (BSE: 532809), an RP-Sanjiv Goenka Group company, today announced the launch of a new offering — Agentic Marketing Services — in partnership with Typeface, the marketing orchestration engine for the world’s leading enterprises. The offering is designed to help enterprises move from marketing ambition to scale by transforming, implementing, and operating AI-native marketing systems. It transforms marketing operations into a scalable growth engine and delivers measurable top-line revenue growth beyond operational efficiency alone.
Agentic AI is redefining how enterprises think about the customer lifecycle, and marketing content sits at the center of that transformation. Enterprises deploying AI-driven personalization are seeing up to 40% higher revenue compared to their peers. Content operations is both a growth lever and an efficiency play for CMOs: roughly 30% of CMO budgets go to content; approximately 55% of content work is manual — resizing, localization, brand compliance — while 90% of those manual workflows can be AI-enabled.
“At Firstsource, our approach has been about moving beyond traditional boundaries to build adaptive, intelligence-led ecosystems that deliver measurable outcomes. Content operations is now the most disrupted layer of the modern marketing stack, with Large Language Models reshaping the entire value chain — from ideation and production to governance and distribution — making it both the biggest near-term efficiency opportunity and the most exposed surface area in enterprise marketing,” said Ritesh Idnani, MD and Chief Executive Officer of Firstsource.
“CEOs and CMOs are not looking for a consultancy that hands off a roadmap or an agency that operates in silos — they want a partner who can transform, implement, and operate marketing systems end-to-end. By combining micro-segmentation, personalization, and deep industry context, we help clients build acquisition, engagement, and retention engines that are intelligent, compliant, and scalable. Typeface brings the AI technology to generate personalized, on-brand, compliant content at scale, and Firstsource brings deep experience in customer operations, especially in regulated industries like banking, financial services, healthcare, and retail. Together, we enable enterprises to plan, build, and run modern marketing — turning content operations into a compounding growth engine and delivering outcomes, not just effort.”
The partnership extends the capabilities announced with Typeface’s recent Marketing Orchestration Engine launch — bringing governed AI systems into full-stack marketing operations for regulated enterprises.
“AI only transforms marketing when it’s embedded into the workflows that drive real customer outcomes,” said Abhay Parasnis, Founder & CEO of Typeface. “Firstsource brings deep industry expertise and operational rigor in highly regulated environments. Together, we’re helping enterprises turn AI ambition into operational reality, embedding governed intelligence into the systems that power durable growth.”
While Typeface provides the orchestration layer that unifies brand intelligence, AI agents, and enterprise systems, Firstsource brings the operational expertise and insights to enable effective decision making and implement and run these systems in complex, regulated environments. Together, they redesign how growth is driven — focusing on the moments, segments, and mechanisms that truly move the needle — enabling enterprises to shift from fragmented activity to scalable, revenue-led execution.
Industry view
“In retail, seasonality and micro-segmentation are where revenue is won or lost. Every peak moment demands thousands of personalized variants across marketing, service, and customer operations — and the retailers who get this right see real movement on acquisition, conversion, and retention, not just efficiency. What makes the Firstsource–Typeface offering different is that it is not another tool — it is an operating capability. Pairing agentic AI with embedded marketing operations is exactly what retailers need to move from broad campaigns to true lifecycle-driven engagement. For the industry, this is a meaningful step-change in how growth gets engineered.”
– Dave Kimbell, Ex-CEO Ulta Beauty; Firstsource Advisory Board Member
“Healthcare payers sit on a real paradox: a huge share of member communication is locked inside PHI and claims workflows where the rules are clear and rightly strict — but the biggest lever on affordability lives outside that envelope, in how payers engage members on wellness, prevention, plan literacy, and proactive disease management. That is a white-space opportunity the industry has barely touched. This is where marketing AI services can genuinely move the needle. With micro-segmentation and agentic content, payers can reach the right member with the right nudge at the right moment — entirely within compliant, non-PHI pathways — and shift the engagement model from acquisition and retention to lifelong wellness. That is how you make healthcare more affordable, improve member experience, and strengthen the economics of the plan at the same time. The Firstsource–Typeface offering is one of the few capabilities purpose-built to operate at that intersection of compliance, personalization, and outcomes.”
– Paul Sanford, Ex-EVP Operations, Cigna Group; Firstsource Advisory Board Member
About Firstsource
Firstsource Solutions Limited, an RP-Sanjiv Goenka Group company (NSE: FSL) (BSE: 532809), is a global intelligence partner to enterprises across healthcare, banking and financial services, communications, media, technology, retail, and utilities. Its inch-wide, mile-deep practitioners work collaboratively to reimagine business process management.
With operations across the US, UK, India, Philippines, Mexico, Romania, Trinidad & Tobago, South Africa, and Australia, Firstsource combines over twenty-five years of domain expertise with an agent-first delivery model to design, build, and operate intelligent enterprise operations. Through its Intelligence That Operates promise—powered by Kairos, the operating system that makes it real—the company unifies consulting, implementation, and operations into a single full-stack engagement and underwrites outcomes, not effort, turning deep domain intelligence into a compounding operational advantage for firms in the world’s most regulated industries. (www.firstsource.com)
About Typeface
Typeface is a marketing orchestration engine for the world’s leading enterprises, coordinating brand intelligence, AI agents, and enterprise systems across cross-channel marketing operations. Built for large organizations, Typeface combines shared brand intelligence, governed agent workflows, and deep enterprise integration at scale — connecting seamlessly with platforms like Salesforce, Microsoft, and Google — to help teams scale what works without sacrificing quality or control. Trusted by Fortune 500 companies, Typeface enables organizations to operationalize AI inside real marketing workflows, turning brand standards, approvals, and performance signals into coordinated systems that improve over time. Typeface is backed by Lightspeed, GV, Salesforce Ventures, Madrona, Menlo, and M12, and has been recognized by Fast Company, Gartner, TIME, LinkedIn, and Adweek as a leader in AI for marketing. Learn more at www.typeface.ai.
View original content:https://www.prnewswire.co.uk/news-releases/firstsource-partners-with-typeface-to-launch-agentic-marketing-services-302759005.html
News Wire
Shaping Future-Ready School Leaders: Woxsen University Leads Design Thinking Initiative for Principals
HYDERABAD, India, April 30, 2026 /PRNewswire/ — The School of Arts and Design at Woxsen University, in collaboration with the Public-School Principals’ Association (PSPA), conducted a Principal Leadership Programme on April 27, bringing together 30 principals from leading schools across Hyderabad for an immersive, design-led learning experience focused on rethinking leadership in contemporary education.
Participating institutions included Delhi Public School, Sloka International School (Tukkuguda), Jain Heritage Cambridge School, AVN Vida International School, CMR School (Medchal), and Gitanjali High School, among others. Designed as a hands-on, studio-based workshop, the programme moved beyond traditional formats, enabling participants to engage in collaborative problem-solving, systems thinking, and real-world leadership challenges.
The programme was delivered by Woxsen’s Centre for Learning Design (CLD) and the David Dunne Design Thinking Lab, and was guided by the university’s ERS (Ethics, Responsibility and Sustainability) framework, reflecting an integrated and purpose-driven approach to leadership development.
Through guided design thinking exercises, principals explored new approaches to decision-making, innovation in school ecosystems, and building student-centric learning environments. The interactive format encouraged peer exchange and practical application, making the experience directly relevant to institutional leadership.
Rajendra Prasad, President of the PSPA, said, “The School Principals’ Leadership Workshop at Woxsen University was well organized and delivered with great impact. The sessions were highly engaging and insightful, and the programme received overwhelming positive feedback from participants for both its content and overall experience.”
Dr. Ashok Pandey, Member of the PSPA Leadership Team, shared, “An inspiring day at the picturesque Woxsen University campus, engaging with exceptional school leaders committed to designing the schools of tomorrow.”
Dr. Adity Saxena, Dean, School of Arts & Design, said, “This programme is aligned with Woxsen’s core pillar of Ethics, Responsibility and Sustainability, reinforcing our commitment to purpose-driven education. We see our role as bridging ideas, institutions, and impact in education, and we are grateful to PSPA and Rajendra Prasad for this meaningful collaboration.”
The initiative reflects Woxsen University’s commitment to strengthening the school education ecosystem in Telangana by building leadership capacity and fostering future-ready thinking among educators. Following the workshop, the PSPA leadership team engaged in a strategic discussion with Dr. Adity Saxena to explore future collaboration opportunities.
Building on the momentum of the programme, Woxsen University and PSPA are exploring the launch of a structured Principal Leadership Certificate Programme. The proposed initiative aims to institutionalize leadership development for school heads and further strengthen the region’s education ecosystem through sustained, practice-oriented engagement.
About Woxsen University, Hyderabad
Woxsen University, located in Hyderabad, is one of the first private universities in the state of Telangana, India. Renowned for its 200-acre state-of-the-art campus and infrastructure, Woxsen University offers new-age, disruptive programs in the fields of Business, Technology, Arts & Design, Architecture, Law, and Liberal Arts & Humanities. Woxsen also houses Asia’s largest Sports Infrastructure, spread over 60 acres. With 175 Global Partner Universities and a strong industry connect, Woxsen is recognized as one of the top universities for Academic Excellence and Global Edge. Woxsen has also secured the QS Business Masters World Ranking 2025, Rank #9 All India, Top 100 B-Schools by Times B-School Ranking 2025, Rank #6, Asia Pacific, Bloomberg Best B-School, and features in India’s Best B-Schools beyond IIMs by Dalal Street Investment Journal 2025, in 4th consecutive year. Woxsen is ranked as one of the Top Professional Colleges in India by Outlook I-CARE for its undergraduate programs, securing All India Rank 12 among the Top 130 BBA Private Institutes, All India Rank 20 among the Top 160 B.Tech Private Institutes, All India Rank 3 among the Top 25 Design Private Institutes, and All India Rank 3 among the Top 30 B. Arch Private Institutes.
Photo: https://oyefilmy.com/wp-content/uploads/2026/04/shaping-future-ready-school-leaders-woxsen-university-leads-design-thinking-initiative-for-principals-1.jpg
Photo: https://oyefilmy.com/wp-content/uploads/2026/04/shaping-future-ready-school-leaders-woxsen-university-leads-design-thinking-initiative-for-principals-2.jpg
Logo: https://mma.prnewswire.com/media/1771070/5365059/Woxsen_University_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/shaping-future-ready-school-leaders-woxsen-university-leads-design-thinking-initiative-for-principals-302758443.html
News Wire
HarperCollins is proud to announce the publication of The Book of Daily Brilliance: 111 Days to Transformation by Pamela Puja Kirpalani
Published by HarperCollins
Hardback | Non-Fiction/Self-Help | 140 pp | INR 399
Available wherever books are sold | Releasing on 24 April 2026
NEW DELHI, April 29, 2026 /PRNewswire/ — HarperCollins Publishers India is thrilled to announce the publication of The Book of Daily Brilliance: 111 Days to Transformation by Pamela Puja Kirpalani, a practical guide towards a spiritual and psychological transformation.
ABOUT THE BOOK
Everyone in the world has good days and bad days. But what if there was a way to unleash one’s radiant self every day? Something simple yet profound—something the reader could reach for every day to centre themselves and remember what really matters.
The Book of Daily Brilliance is designed to speak to the heart and the highest self. Meant to be read over 111 days and covering topics that resonate with all—relationships, self-worth, love, pain, abundance, manifestation, surrender and much more—this daily reader will guide the one through a gentle yet powerful spiritual and psychological journey.
There is no fixed start date. No pressure to be perfect. If a day is skipped or there is a pause for a while, that is okay. All that’s needed to do is come back when it feels right. For those who choose to commit to the 111-day journey, the experience reveals the unfolding of a deeper truth within.
So, take a deep breath. Open the page to Day 1 and let this be an invitation to return to oneself —one day, one page, one insight at a time.
Pamela Puja Kirpalani says, “One page can really just change the way you show up for your life. I wrote The Book of Daily Brilliance to be something you return to, not just read once — a daily pause that brings clarity, perspective and healing. In a fast-paced world, I believe even a single mindful page a day can create powerful inner psychological shifts. This 111 Daily Reader is my way of helping people reconnect with themselves— and if it helps someone feel more present, more grounded, and more like themselves, then it has done exactly what I hoped it would.”
Sachin Sharma, Publisher, HarperCollins India, says, “The Book of Daily Brilliance offers a perfect pause amidst the busyness of life. Readers will appreciate how the book gently guides them through a journey of transformation—without any pressure—one step, one day at a time.”
ABOUT THE AUTHOR
Pamela Puja Kirpalani is the Founder of Inner High Living and a distinguished thought leader in the world of behavioural psychology and neuro-behaviour. Her vision materialized as she started coaching individuals, couples and parents on achieving their goals initially using Neuro-linguistic Programming (NLP) as a modality. She is certified by ABNlp (Australian Board of Neuro-Linguistic Programming), IEMT (Integrated Eye Movement Technique) Practitioner, member of the APSS Singapore and the NLP Association of Singapore.
ABOUT HARPERCOLLINS INDIA
At HarperCollins Publishers India, we believe in telling the best stories and ensuring they reach the widest readership. We publish around 250 new books every year across 10 imprints, adding to a diverse catalogue of more than 2,000 titles across print and digital formats. Our authors include APJ Abdul Kalam, Agatha Christie, Amish Tripathi, Amitav Ghosh (Erasmus Prize 2024), Jhumpa Lahiri, Paulo Coelho, Raghuram Rajan, Sudha Murty, Ruskin Bond and many more.
HarperCollins India has been honoured with seven Publisher of the Year awards and proudly represents global publishers such as Harvard University Press, Lonely Planet, Oneworld, Nosy Crow, Usborne and National Geographic Children.
We have also been certified as a Great Place to Work for two consecutive years, a testament to our culture, creativity and people.
Photo: https://oyefilmy.com/wp-content/uploads/2026/04/harpercollins-is-proud-to-announce-the-publication-of-the-book-of-daily-brilliance-111-days-to-transformation-by-pamela-puja-kirpalani-1.jpg
Logo: https://mma.prnewswire.com/media/2105077/4665143/HarperCollins_Logo.jpg
View original content to download multimedia:https://www.prnewswire.com/in/news-releases/harpercollins-is-proud-to-announce-the-publication-of-the-book-of-daily-brilliance-111-days-to-transformation-by-pamela-puja-kirpalani-302757097.html
Firstsource Partners with Typeface to Launch Agentic Marketing Services
Firstsource Partners with Typeface to Launch Agentic Marketing Services
Shaping Future-Ready School Leaders: Woxsen University Leads Design Thinking Initiative for Principals
-
News Wire2 months agoCrocs™ brings KL Rahul on board as brand ambassador with ‘Play Hard. Rest Easy.’ Campaign
-
Buzz2 months agoIndia Emerging as Stable Investment Anchor in Turbulent Global Economy, Say Investors at IGF Mumbai 2026
-
News Wire2 months agoIIT Delhi Spinout DeepLase Raises ₹6 Crore Seed Round co-led by Kavachh and Yali Capital
-
Buzz2 months ago
IIT Delhi Spinout DeepLase Raises ₹6 Crore Seed Round co-led by Kavachh and Yali Capital
-
News Wire2 months agoBengaluru-based TerraTern Emerges As a Global Hub for AI-Powered Immigration, Work & Study Abroad Guidance
-
Buzz2 months agoFrom Rural Roots to Global Impact: Ruma Devi on Women, Craft and Purpose on Herbalife India’s Podcast Live Your Best Life, Unscripted
-
Buzz2 months agoIndia Global Forum Returns to Mumbai for Third Edition as Global Markets Navigate Volatility and Geopolitical Fragmentation
-
Buzz2 months agoCJ 4DPLEX’S MULTISENSORY 4DX PREMIUM FORMAT DELIVERS RECORD-BREAKING GROWTH IN INDIA IN 2025
You must be logged in to post a comment Login